240 related articles for article (PubMed ID: 35093157)
1. Whole-body MRI evaluation in neurofibromatosis type 1 patients younger than 3 years old and the genetic contribution to disease progression.
Kang E; Kim YM; Choi Y; Lee Y; Kim J; Choi IH; Yoo HW; Yoon HM; Lee BH
Orphanet J Rare Dis; 2022 Jan; 17(1):24. PubMed ID: 35093157
[TBL] [Abstract][Full Text] [Related]
2. Clinical Value of Multiparametric Whole-Body Magnetic Resonance Imaging over Whole-Spine Magnetic Resonance Imaging in Patients with Neurofibromatosis Type I.
Zhang L; Dessouky R; Xi Y; Chhabra A; Le LQ
World Neurosurg; 2017 Dec; 108():729-737. PubMed ID: 28939538
[TBL] [Abstract][Full Text] [Related]
3. Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomics.
Liu Y; Jordan JT; Bredella MA; Erdin S; Walker JA; Vangel M; Harris GJ; Plotkin SR; Cai W
Neurology; 2020 Jun; 94(24):e2521-e2531. PubMed ID: 32345730
[TBL] [Abstract][Full Text] [Related]
4. Association of plexiform and diffuse neurofibromas with malignant peripheral nerve sheath tumor in NF I patients: a whole-body MRI assessment.
Attia S; Guirguis M; Le LQ; Chhabra A
Skeletal Radiol; 2024 Apr; 53(4):769-777. PubMed ID: 37903998
[TBL] [Abstract][Full Text] [Related]
5. Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRI.
Ly KI; Merker VL; Cai W; Bredella MA; Muzikansky A; Thalheimer RD; Da JL; Orr CC; Herr HP; Morris ME; Chang CY; Harris GJ; Plotkin SR; Jordan JT
Neurology; 2023 Feb; 100(7):e661-e670. PubMed ID: 36332985
[TBL] [Abstract][Full Text] [Related]
6. Optic Pathway Glioma and Cerebral Focal Abnormal Signal Intensity in Patients with Neurofibromatosis Type 1: Characteristics, Treatment Choices and Follow-up in 134 Affected Individuals and a Brief Review of the Literature.
Friedrich RE; Nuding MA
Anticancer Res; 2016 Aug; 36(8):4095-121. PubMed ID: 27466519
[TBL] [Abstract][Full Text] [Related]
7. The effect of pregnancy on growth-dynamics of neurofibromas in Neurofibromatosis type 1.
Well L; Jaeger A; Kehrer-Sawatzki H; Farschtschi S; Avanesov M; Sauer M; de Sousa MT; Bannas P; Derlin T; Adam G; Mautner VF; Salamon JM
PLoS One; 2020; 15(4):e0232031. PubMed ID: 32343738
[TBL] [Abstract][Full Text] [Related]
8. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1.
Mautner VF; Asuagbor FA; Dombi E; Fünsterer C; Kluwe L; Wenzel R; Widemann BC; Friedman JM
Neuro Oncol; 2008 Aug; 10(4):593-8. PubMed ID: 18559970
[TBL] [Abstract][Full Text] [Related]
9. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors.
Salamon J; Mautner VF; Adam G; Derlin T
Rofo; 2015 Dec; 187(12):1084-92. PubMed ID: 26333104
[TBL] [Abstract][Full Text] [Related]
10. Tumor segmentation of whole-body magnetic resonance imaging in neurofibromatosis type 1 patients: tumor burden correlates.
Heffler MA; Le LQ; Xi Y; Chhabra A
Skeletal Radiol; 2017 Jan; 46(1):93-99. PubMed ID: 27815599
[TBL] [Abstract][Full Text] [Related]
11. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
Urban T; Lim R; Merker VL; Muzikansky A; Harris GJ; Kassarjian A; Bredella MA; Plotkin SR
Clin Nucl Med; 2014 May; 39(5):e301-7. PubMed ID: 24152623
[TBL] [Abstract][Full Text] [Related]
12. C2 neurofibromas in neurofibromatosis type 1: genetic and imaging characteristics.
Waqar M; Huson S; Evans DG; Ealing J; Karabatsou K; George KJ; Soh C
J Neurosurg Spine; 2018 Oct; 30(1):126-132. PubMed ID: 30485203
[TBL] [Abstract][Full Text] [Related]
13. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.
Plotkin SR; Bredella MA; Cai W; Kassarjian A; Harris GJ; Esparza S; Merker VL; Munn LL; Muzikansky A; Askenazi M; Nguyen R; Wenzel R; Mautner VF
PLoS One; 2012; 7(4):e35711. PubMed ID: 22558206
[TBL] [Abstract][Full Text] [Related]
14. Genotype-phenotype correlation in neurofibromatosis type-1: NF1 whole gene deletions lead to high tumor-burden and increased tumor-growth.
Well L; Döbel K; Kluwe L; Bannas P; Farschtschi S; Adam G; Mautner VF; Salamon J
PLoS Genet; 2021 May; 17(5):e1009517. PubMed ID: 33951044
[TBL] [Abstract][Full Text] [Related]
15. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas.
Tucker T; Friedman JM; Friedrich RE; Wenzel R; Fünsterer C; Mautner VF
J Med Genet; 2009 Feb; 46(2):81-5. PubMed ID: 18930997
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromatosis type 1 and the pediatric neurosurgeon: a 20-year institutional review.
Farmer JP; Khan S; Khan A; Ortenberg J; Freeman C; O'Gorman AM; Montes J
Pediatr Neurosurg; 2002 Sep; 37(3):122-36. PubMed ID: 12187057
[TBL] [Abstract][Full Text] [Related]
17. Clinical characterization of children and adolescents with NF1 microdeletions.
Kehrer-Sawatzki H; Kluwe L; Salamon J; Well L; Farschtschi S; Rosenbaum T; Mautner VF
Childs Nerv Syst; 2020 Oct; 36(10):2297-2310. PubMed ID: 32533297
[TBL] [Abstract][Full Text] [Related]
18. [Phenotypic and genetic features in neurofibromatosis type 1 in children].
Duat Rodríguez A; Martos Moreno GÁ; Martín Santo-Domingo Y; Hernández Martín A; Espejo-Saavedra Roca JM; Ruiz-Falcó Rojas ML; Argente J
An Pediatr (Barc); 2015 Sep; 83(3):173-82. PubMed ID: 25541118
[TBL] [Abstract][Full Text] [Related]
19. Association between benign and malignant peripheral nerve sheath tumors in NF1.
Tucker T; Wolkenstein P; Revuz J; Zeller J; Friedman JM
Neurology; 2005 Jul; 65(2):205-11. PubMed ID: 16043787
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
